卖什么
AI癌症研究。
商业模式拆解
买家：谁掌握预算？
未核实Business development and R&D leads at pharma and biotech, and investors evaluating combination trials.
触发点：什么让他们现在购买？
Resistant cells regrow after standard of care; need to find the one or two effective combinations among 60+ billion; want a sense check before running a combination trial.
工作流：什么输入变成什么输出？
Model ranks combinations in seconds; partners ask for the right pairing within a portfolio or delivery cargo or a sense check of a trial, with a first free check within hours, then deeper collaboration.
经济账：省了什么，怎么收费？
Builds internal combination programs and works with pharma/biotech/investors (partnership model); validation claim of 86% accuracy on ASCO 2026 prospective calls.
渠道：怎么接触到客户？
Email outreach and public prediction posts on X.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| 2026-09-18 | — | 2,55 Millionen Euro | — | news.google.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.